Over 10 years we help companies reach their financial and branding goals. Maxbizz is a values-driven consulting agency dedicated.

Gallery

Contact

+1-800-456-478-23

411 University St, Seattle

maxbizz@mail.com

Sona Nanotech to Present Targeted Hyperthermia Therapy at the 19th International Canadian Melanoma Conference

Sona Nanotech to Present Targeted Hyperthermia Therapy at the 19th International Canadian Melanoma Conference

Halifax, Nova Scotia – (Newsfile Corp. – February 12, 2025) – Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) is pleased to announce that recently published findings from its “Targeted Intra-tumoral Hyperthermia with Uniquely Biocompatible Gold Nanorods Induces a Strong Immunogenic Cell Death in Two Immunogenically ‘Cold’ Tumors” study will be presented at the International 19th Canadian Melanoma Conference on February 20th in Vancouver. Sona’s Chief Medical Officer, Dr. Carman Giacomantonio, a planning committee member for this conference, and Dr. Barry Kennedy, of The Giacomantonio Immuno-Oncology Research Group, will present both poster and oral presentations.

Torrent Capital Increases its Solana Holdings

Torrent Capital Increases its Solana Holdings

Torrent Capital Ltd., (TSXV: TORR), (“Torrent”) announces it has acquired an additional 4,955 Solana (SOL) tokens since January 6, 2025, when it announced the creation of a cryptocurrency portfolio and initial SOL purchases. As of February 10, 2025, Torrent held a total of 6,955 SOL, which are generating a yield from staking rewards.

Antler Gold Secures Shareholder and Regulatory Approvals for Amended Erongo Gold Project Agreement

Antler Gold Secures Shareholder and Regulatory Approvals for Amended Erongo Gold Project Agreement

Antler Gold Inc. (“Antler” or the “Company”) (TSXV: ANTL) is pleased to announce that it has received the requisite shareholder approval and regulatory approval from the TSX Venture Exchange for the amending agreement dated December 5, 2024 (the “Amending Agreement”) to the agreement with Fortress Asset Management LLC (“Fortress”) dated September 18, 2024 in respect of the Erongo Central Gold Project (the “Project”) in Namibia.

Offering Document Under the Listed Issuer Financing Exemption

Offering Document Under the Listed Issuer Financing Exemption

This Offering Document (the “Offering Document”) constitutes an offering of these securities only in those jurisdictions where they may be lawfully offered for sale and therein only by persons permitted to sell such securities and to those persons to whom they may be lawfully offered for sale. This Offering Document is not, and under no circumstances is to be construed as a prospectus or advertisement or a public offering of these securities.

Torrent Capital Announces up to $5.0 Million Prospectus Exempt Offering Pursuant to the Listed Issuer Financing Exemption and up to $5.0 Million Concurrent Private Placement

Torrent Capital Announces up to $5.0 Million Prospectus Exempt Offering Pursuant to the Listed Issuer Financing Exemption and up to $5.0 Million Concurrent Private Placement

Torrent Capital Ltd. (TSXV: TORR) (the “Company” or “Torrent“) is pleased to announce a “best efforts” prospectus exempt offering (the “LIFE Offering“) of up to 7,142,857 units (the “Units“) of the Company at a price of $0.70 per Unit (the “Issue Price“) for gross proceeds of up to $5,000,000, pursuant to the listed issuer financing exemption available under Part 5A of National Instrument 45-106 – Prospectus Exemptions (“NI 45-106“) to purchasers resident in each of the provinces of Canada, other than Quebec, and other qualifying jurisdictions. The Units offered under the LIFE Offering will not be subject to a statutory hold period in accordance ‎with applicable Canadian securities laws.‎
The cryptocurrency market has experienced remarkable growth over the past decade, evolving from a niche asset class to a globally recognized financial ecosystem.

Sona Nanotech’s THT Cancer Therapy Preclinical Efficacy Studies Published In Peer-reviewed Scientific Journal

Sona Nanotech’s THT Cancer Therapy Preclinical Efficacy Studies Published In Peer-reviewed Scientific Journal

Sona Nanotech Inc. (CSE: SONA, OTCQB: SNANF) (the “Company”, “Sona”) is pleased to announce that the now complete findings from our previously announced pre-clinical breast cancer and melanoma efficacy studies have been published in the peer-reviewed scientific journal, Frontiers in Immunology. This research article includes new follow-up data which provides a comprehensive analysis of the immunity activated by Sona’s Targeted Hyperthermia Therapy (“THT”). The published manuscript titled, “Targeted Intra-tumoral Hyperthermia with Uniquely Biocompatible Gold Nanorods Induces a Strong Immunogenic Cell Death in Two Immunogenically ‘Cold’ Tumors” is available online in electronic form here and will be in print in its upcoming issue of Frontiers in Immunology – Cancer Immunology and Immunotherapy. Frontiers in Immunology is a leading journal in its field, publishing rigorously peer-reviewed research across basic, translational and clinical immunology.

Torrent Capital Initiates a Position in Solana Cryptocurrency

Torrent Capital Initiates a Position in Solana Cryptocurrency

Torrent Capital Ltd., (TSXV: TORR), (“Torrent”) announces it has created a cryptocurrency investment portfolio and acquired 2,000 tokens of Solana (SOL) cryptocurrency. The Solana tokens have been staked and are generating yield.

The cryptocurrency market has experienced remarkable growth over the past decade, evolving from a niche asset class to a globally recognized financial ecosystem.

Sona Nanotech’s THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech’s THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy (“THT”) which uses the Company’s patented, biocompatible gold nanorods (“GNRs”) to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company’s third preclinical efficacy study was conducted in an immunologically ‘cold’ colorectal cancer model (“CT26”), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.